Literature DB >> 23535831

Osteoprotegerin as a marker of cardiovascular risk in patients on peritoneal dialysis.

Katarzyna Janda1, Marcin Krzanowski, Eve Chowaniec, Beata Kuśnierz-Cabala, Paulina Dumnicka, Andrzej Kraśniak, Piotr Podolec, Władysław Sułowicz.   

Abstract

INTRODUCTION: Arterial thickening contributes to elevated cardiovascular risk in patients on maintenance renal replacement therapy. The common carotid artery intima-media thickness (CCA-IMT) is an early atherosclerotic marker and may be used to assess the stratification of atherosclerotic advancement and resultant arterial calcification.
OBJECTIVES: The aim of the study was to evaluate the associations between atherosclerotic changes in the common carotid arteries expressed as the CCA-IMT and the body mass index (BMI), serum lipid levels, C‑reactive protein (CRP), and selected bone metabolism parameters including phosphorus, calcium, intact parathormone (iPTH), alkaline phosphatase, osteopontin, osteoprotegerin, osteocalcin, fetuin A, and fibroblast growth factor‑23 (FGF‑23) in patients treated with peritoneal dialysis. PATIENTS AND METHODS: The study included 67 patients with chronic kidney disease (36 men and 31 women) aged 53 ±13 years (range, 19-75 years) treated with peritoneal dialysis for 30 ±24 months. The CCA‑IMT was assessed by ultrasonography using Acuson 128/10 XP. The BMI was calculated using the Quetelet formula. Serum lipid levels, phosphorus, calcium, iPTH, alkaline phosphatase, and CRP were measured using standard laboratory methods, while fetuin A, osteocalcin, osteoprotegerin, osteopontin, and FGF‑23 using commercial enzyme‑linked immunosorbent assay kits.
RESULTS: Positive correlations were observed between CCA-IMT and age (r = 0.54, P <0.0001), BMI (r = 0.39, P = 0.003), and osteoprotegerin (r = 0.38, P = 0.004). In a multiple regression analysis, age (r = 0.41, P = 0.01), osteocalcin (r = 0.34, P = 0.04), and log‑transformed osteoprotegerin values (r = 0.38, P = 0.02) remained independently associated with the CCA-IMT. The highest CCA‑IMT values (0.85 ±0.21) were observed in patients with osteoprotegerin concentrations in the upper tertile. Osteoprotegerin concentrations strongly and positively correlated with the duration of dialysis treatment (r = 0.55, P <0.0001).
CONCLUSIONS: The CCA‑IMT has been shown to be a reliable noninvasive measure of subclinical atherosclerosis and, therefore, of associated increased vascular risk. Elevated serum osteoprotegerin levels may be useful as a prognostic marker of cardiovascular risk in dialyzed patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23535831     DOI: 10.20452/pamw.1678

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  11 in total

Review 1.  Osteoprotegerin and kidney disease.

Authors:  Alejandra Montañez-Barragán; Isaias Gómez-Barrera; Maria D Sanchez-Niño; Alvaro C Ucero; Liliana González-Espinoza; Alberto Ortiz
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

2.  FGF-23 levels are associated with vascular calcification, but not with atherosclerosis, in hemodialysis patients.

Authors:  Mehmet Nuri Turan; Fatih Kircelli; Mustafa Yaprak; Ali Riza Sisman; Ozkan Gungor; Selen Bayraktaroglu; Mehmet Ozkahya; Gulay Asci; Jurgen Floege; Ercan Ok
Journal:  Int Urol Nephrol       Date:  2016-02-10       Impact factor: 2.370

3.  Osteoprotegerin Is a Better Predictor for Cardiovascular and All-Cause Mortality than Vascular Calcifications in a Multicenter Cohort of Patients on Peritoneal Dialysis.

Authors:  Marcela Ávila; Ma Del Carmen Prado; Renata Romero; Ricardo Córdova; Ma Del Carmen Rigo; Miguel Trejo; Carmen Mora; Ramón Paniagua
Journal:  Biomolecules       Date:  2022-04-08

4.  Cardiovascular risk in chronic kidney disease patients: intima-media thickness predicts the incidence and severity of histologically assessed medial calcification in radial arteries.

Authors:  Katarzyna Janda; Marcin Krzanowski; Mariusz Gajda; Paulina Dumnicka; Danuta Fedak; Grzegorz J Lis; Piotr Jaśkowski; Agata Pietrzycka; Jan A Litwin; Władysław Sułowicz
Journal:  BMC Nephrol       Date:  2015-06-03       Impact factor: 2.388

Review 5.  New antiresorptive therapies for postmenopausal osteoporosis.

Authors:  Hee-Jeong Choi
Journal:  J Menopausal Med       Date:  2015-04-27

6.  Impaired fasting glucose and diabetes as predictors for radial artery calcification in end stage renal disease patients.

Authors:  Katarzyna Janda; Marcin Krzanowski; Mariusz Gajda; Paulina Dumnicka; Danuta Fedak; Grzegorz J Lis; Piotr Jaśkowski; Jan A Litwin; Władysław Sułowicz
Journal:  Int J Endocrinol       Date:  2013-12-18       Impact factor: 3.257

7.  Osteocalcin, Vascular Calcification, and Atherosclerosis: A Systematic Review and Meta-analysis.

Authors:  Sophie A Millar; Hinal Patel; Susan I Anderson; Timothy J England; Saoirse E O'Sullivan
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-31       Impact factor: 5.555

8.  Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients.

Authors:  Rafał Donderski; Paweł Stróżecki; Beata Sulikowska; Magdalena Grajewska; Ilona Miśkowiec; Anna Stefańska; Joanna Siódmiak; Grażyna Odrowąż-Sypniewska; Jacek Manitius
Journal:  Int Urol Nephrol       Date:  2017-07-14       Impact factor: 2.370

9.  Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients.

Authors:  Panagiotis Pateinakis; Aikaterini Papagianni; Stella Douma; Georgios Efstratiadis; Dimitrios Memmos
Journal:  BMC Nephrol       Date:  2013-06-12       Impact factor: 2.388

10.  A biomarker, osteoprotegerin, in patients undergoing hemodialysis.

Authors:  Gang Jee Ko
Journal:  Korean J Intern Med       Date:  2013-10-29       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.